Laboratorio Of Oncogenomica

Dolores Hidalgo Cuna de la Independencia Nacional, Mexico

Laboratorio Of Oncogenomica

Dolores Hidalgo Cuna de la Independencia Nacional, Mexico
SEARCH FILTERS
Time filter
Source Type

Fernandez-Retana J.,National Autonomous University of Mexico | Fernandez-Retana J.,Laboratorio Of Oncogenomica | Lasa-Gonsebatt F.,Laboratorio Of Oncogenomica | Lopez-Urrutia E.,National Autonomous University of Mexico | And 7 more authors.
Translational Oncology | Year: 2015

Cervical cancer (CC) mortality is a major public health concern since it is the second cause of cancer-related deaths among women. Patients diagnosed with locally advanced CC (LACC) have an important rate of recurrence and treatment failure. Conventional treatment for LACC is based on chemotherapy and radiotherapy; however, up to 40% of patients will not respond to conventional treatment; hence, we searched for a prognostic gene signature able to discriminate patients who do not respond to the conventional treatment employed to treat LACC. Tumor biopsies were profiled with genome-wide high-density expression microarrays. Class prediction was performed in tumor tissues and the resultant gene signature was validated by quantitative reverse transcription–polymerase chain reaction. A 27-predictive gene profile was identified through its association with pathologic response. The 27-gene profile was validated in an independent set of patients and was able to distinguish between patients diagnosed as no response  versus complete response. Gene expression analysis revealed two distinct groups of tumors diagnosed as LACC. Our findings could provide a strategy to select patients who would benefit from neoadjuvant radiochemotherapy-based treatment. © 2015 The Authors.


PubMed | Servicio de Tumores de Mama, Instituto Nacional Of Salud Publica, National Autonomous University of Mexico, Laboratorio Of Oncogenomica and Instituto Nacional Of Nutricion Incmnsz
Type: Journal Article | Journal: Translational oncology | Year: 2015

Cervical cancer (CC) mortality is a major public health concern since it is the second cause of cancer-related deaths among women. Patients diagnosed with locally advanced CC (LACC) have an important rate of recurrence and treatment failure. Conventional treatment for LACC is based on chemotherapy and radiotherapy; however, up to 40% of patients will not respond to conventional treatment; hence, we searched for a prognostic gene signature able to discriminate patients who do not respond to the conventional treatment employed to treat LACC. Tumor biopsies were profiled with genome-wide high-density expression microarrays. Class prediction was performed in tumor tissues and the resultant gene signature was validated by quantitative reverse transcription-polymerase chain reaction. A 27-predictive gene profile was identified through its association with pathologic response. The 27-gene profile was validated in an independent set of patients and was able to distinguish between patients diagnosed as no response versus complete response. Gene expression analysis revealed two distinct groups of tumors diagnosed as LACC. Our findings could provide a strategy to select patients who would benefit from neoadjuvant radiochemotherapy-based treatment.


Castellanos T.,Laboratorio Of Nutrigenomica | Rodriguez D.,Laboratorio Of Oncogenomica
Revista Chilena de Nutricion | Year: 2015

For some years a boom in the field of nutrition related to the beneficial effect of consuming omega-3 fatty acids to human health has taken place. Currently, we can fi nd a variety of supplements in capsules with omega 3 with or without vitamins, minerals and other substances, as well as several foods fortifi ed with omega 3. Many of the scientific research shows that eating certain doses of these fatty acids may have a benefi cial effect on diseases like lupus erythematosus, diabetes mellitus type 2, cancer, atherosclerosis, hyperlipidemia, metabolic syndrome, and others. Due to the strength of its benefi cial effect on cardiovascular disease different international associations issued recommendations for consumption. However, these recommendations, there are some considerations arising from current studies by eating them. So this review aims to give an update on the issue and make account possible disputes arising from the use thereof. © 2015, Sociedad Chilena de Nutricion Bromatologia y Toxilogica. All rights reserved.


Jacobo-Herrera N.J.,Instituto Nacional Of Ciencias Medicas Y Nutricion Salvador Zubiran | Perez-Plasencia C.,National Autonomous University of Mexico | Perez-Plasencia C.,Laboratorio Of Oncogenomica | Camacho-Zavala E.,Instituto Nacional Of Ciencias Medicas Y Nutricion Salvador Zubiran | And 5 more authors.
Oncology Reports | Year: 2014

In the search for new therapeutic alternatives against cancer, either as a preventive treatment or for advanced stages, it is common to appeal to well-known drugs used for the treatment of other diseases that may interfere with the metabolic pathways involved in carcinogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) display anticancer activity through the inhibition of the COX-2 enzyme, triggering processes such as apoptosis, a reduction in proliferation and inhibition of carcinogenesis. Breast cancer is a neoplasm with the highest incidence and mortality rate among young women worldwide. Epidemiologic data have shown that drugs such as NSAIDs, particularly aspirin, reduce the relative risk of breast cancer. However, in the subgroup of responsive patients, dose, time and frequency of use have not yet been established. Here, we review the reports published during the last 10 years regarding the relationship between breast cancer and aspirin.

Loading Laboratorio Of Oncogenomica collaborators
Loading Laboratorio Of Oncogenomica collaborators